Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis

Cécile Gaujoux-Viala and Bruno Fautrel ()
Additional contact information
Cécile Gaujoux-Viala: Université Pierre et Marie Curie (UPMC) Paris VI, GRC-UMPC 08 (EEMOIS)
Bruno Fautrel: Université Pierre et Marie Curie (UPMC) Paris VI, GRC-UMPC 08 (EEMOIS)

PharmacoEconomics, 2012, vol. 30, issue 12, No 5, 1145-1156

Abstract: Abstract Objectives This report reviews the cost effectiveness of different therapeutic interventions used in the treatment of ankylosing spondylitis (AS). Methods We performed a systematic search of the databases MEDLINE via PubMed, EMBASE and the Cochrane Library and used hand-searching to identify articles on cost effectiveness of therapies for adult patients with AS published up to November 2010. Results Of 135 articles, 13 studies were analysed. Two articles were on physical therapies, one article was on NSAIDs and ten articles were on tumour necrosis factor (TNF) inhibitors (infliximab = 6, etanercept = 2, infliximab and etanercept = 1 and adalimumab = 1). Of the latter, no article directly compared TNF inhibitors. Articles showed substantial heterogeneity in methodological approaches and thus results, which prevented us from any extensive comparison, data pooling or meta-analysis. The incremental cost-effectiveness ratio (ICER) for spa-exercise treatment was €7465 (95% CI 3294, 14 686) per QALY. The ICERs for infliximab, etanercept and adalimumab were €5307–237 010, €29 815–123 761 and €7344-33 303 per QALY, respectively. Conclusions Modelling treatment strategies in chronic relapsing diseases such as AS presents specific challenges, as reflected in the variation in the cost-effectiveness results reported. Although quite variable, the cost-effectiveness ratios for AS therapies remain within an acceptable range.

Keywords: Infliximab; Ankylose Spondylitis; Etanercept; Celecoxib; Adalimumab (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.2165/11596490-000000000-00000 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:30:y:2012:i:12:d:10.2165_11596490-000000000-00000

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/11596490-000000000-00000

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().